Bowel cancer, also known as colorectal cancer, is the second most common cancer in Australian men and women. It affects 1 in 13 people. It is also Australia’s second deadliest cancer, with over 5,000 people dying each year. Early detection through screening can improve survival rates, however further research is needed to help find cures and prevent the disease.
The Bowel Cancer and Biomarker Laboratory at the Kolling Institute uses advanced technologies to study the genes and proteins responsible for bowel cancers growing and spreading. Our aim is to use a patient’s own molecular information to understand the risk of bowel cancer developing and to guide treatment options. As part of our research, we are studying how to control bowel polyp growth, which are precursors to cancer. We are doing this through diet and chemotherapy drugs.
The University of Sydney | Northern Clinical School
Faculty of Medicine and Health
Honorary Professor | Dept. Molecular Sciences, Macquarie University
Secretary | Australasian Proteomics Society
Postdoctoral Research Fellow
Postdoctoral Scientist
Matthew McKay - Senior Research Officer
Bharat Venkatesh Gunappa - Research Officer
Atul Bhatnagar - Senior Technical Officer
(Vo Van) Anh Pham - PhD Student
Miguel Castaneda - Research Affiliate
YuHong Fu - Visiting Researcher
Ping (Wendy) Wu - Visiting Research Assistant
Kiera Hicks - Honours Student
Colby Stevenson - PhD Student
Eve Hopping - Masters Student
Elizabeth Brenchley - Masters Student
Gabriella Parrilla - Research Assistant
Current bowel cancer research focuses on:
Our research is facilitated by specimens from clinical projects we run including:
Posted on: 15 November, 2024
We would like to thank everyone involved in the 2024 Kolling Institute Symposium. During the event, ..... Read more
Category: Cardiovascular and Renal Research, Musculoskeletal Research, Neuroscience and Pain Research, Presentations, Research Excellence
Posted on: 12 November, 2024
Our Kolling Institute newsletter brings together a collection of profiles on our impressive research..... Read more
Category: New Treatment, Newsletters, Research Excellence
Posted on: 23 October, 2024
Kolling Institute researcher and Royal North Shore Hospital endocrinologist Professor Rory Clifton-B..... Read more
Category: New Treatment, Research Excellence